Orient Bio Cuts Vice Chair’s Shareholdings in Half Through 2-to-1 Capital Reduction Without Compensation

Orient Bio Vice Chair Choi Suk-jong’s shareholdings fell by half, from 1,644,717 shares to 822,358 shares. According to the Financial Supervisory Service’s electronic disclosure system, Choi was listed as having disposed of 822,359 common shares through a capital reduction on the fourth of this month. Her ownership stake remained unchanged at 2.77% from the previous report. Choi, a registered executive appointed in July 2003 and Orient Bio’s de facto controlling shareholder, saw her share count decline not because of a market sale but as a result of the company’s 2-to-1 share consolidation and the accompanying 50% capital reduction without compensation.

Why the company moved to restructure its finances through a share consolidation

Orient Bio is a biological-materials infrastructure company specializing in the production of laboratory animals, including rodents, beagles and nonhuman primates, as well as contract research organization (CRO) services for nonclinical testing. The capital reduction cut the total number of issued shares from 29,645,751 to roughly half its previous level. Because all shareholders’ holdings were reduced uniformly, individual ownership percentages did not change.

Under rules governing South Korea’s KOSDAQ market, a stock whose price remains below 1,000 won for a certain period may be designated as a managed issue or face the risk of delisting. Experts in South Korea’s financial investment industry have analyzed the recent wave of share consolidations and capital reductions by small and midsize pharmaceutical and biotechnology companies as “a restructuring effort to improve financial conditions by clearing accumulated deficits while reducing the number of shares to shed the penny-stock label and defend listing-maintenance requirements.” Orient Bio’s capital reduction is also understood to have been carried out in the same context.

Immediately after the capital reduction took effect in early September, Orient and parties deemed specially related to the company, including the largest shareholder, increased their combined ownership stake by 0.55 percentage points, from 39.65% to 40.20%, through on- and off-market purchases. The move is viewed as signaling both an intention to stabilize management control and confidence in the company’s value.

Investment capacity secured through a return to profitability and debt-free management

Orient Bio pursued extensive production efficiencies, including the integration of its Gapyeong Centers 1 and 2, cutting operating expenses by 29.7% from the same period a year earlier. As a result, the company returned to profitability in its first-quarter results for April through June, announced in August 2026, posting operating profit of 100 million won and net income of 4.8 billion won. Under its debt-free management policy, which has continued since 2023, its debt ratio is only about 19%, while cash and cash equivalents total approximately 38 billion won, leaving it with ample liquidity for investment in new businesses.

An Orient Bio official said, “The sound-management and operational-efficiency strategies we have pursued are beginning to bear full fruit starting this quarter,” adding, “Based on our stable financial structure, we will strengthen future growth engines, including the nonhuman primate CRO business and an artificial intelligence (AI) biotechnology platform, to enhance corporate value.”

Although South Korea is emerging as a global pharmaceutical and biotechnology powerhouse, its research laboratory-animal infrastructure has remained highly dependent on imports. Orient Bio’s recent completion of a specific pathogen-free (SPF) rabbit production facility in Jeongeup, North Jeolla province, and its technology partnerships with global companies are viewed as strategic moves to increase the self-sufficiency of South Korea’s biotechnology supply chain and reduce risks associated with import quarantine.

Expansion of the nonhuman primate CRO business and new ventures will be key turning points

Having laid the groundwork for a return to profitability through financial restructuring and cost reductions, Orient Bio is expected to focus on expanding its high-value-added nonhuman primate contract research business for nonclinical testing. As research and development investment by major global pharmaceutical companies increases, demand for nonhuman primate studies is surging, potentially expanding business opportunities for Orient Bio, which has CRO infrastructure in Asia, analysts say.

With management control further stabilized by the largest shareholder’s increased stake, the results of developing the nonhormonal hair-loss treatment OND-1 and the market acceptance of the newly launched AI biotechnology platform business are considered key factors that will determine Orient Bio’s medium- to long-term corporate value.